

eXegenics Inc
 Form 3
 April 06, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|--|---|--|--|---|---|
| <p>1. Name and Address of Reporting Person *</p> <p>Â JOHNSON & JOHNSON</p> <p>(Last) (First) (Middle)</p> <p>ONE JOHNSON & JOHNSON PLAZA</p> <p>(Street)</p> <p>NEW BRUNSWICK,Â NJÂ 08933</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>03/27/2007</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>eXegenics Inc [EXEG]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>___ Director ___X_ 10% Owner ___ Officer ___ Other (give title below) (specify below)</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p>_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person</p> |
|--|---|--|--|---|---|

Table I - Non-Derivative Securities Beneficially Owned

| | | | |
|--|--|---|--|
| <p>1. Title of Security (Instr. 4)</p> | <p>2. Amount of Securities Beneficially Owned (Instr. 4)</p> | <p>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</p> | <p>4. Nature of Indirect Beneficial Ownership (Instr. 5)</p> |
|--|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | | | |
|---|--|---|---|---|--|
| <p>1. Title of Derivative Security (Instr. 4)</p> | <p>2. Date Exercisable and Expiration Date (Month/Day/Year)</p> <p>Date Exercisable Expiration Date</p> | <p>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</p> <p>Title Amount or Number of Shares</p> | <p>4. Conversion or Exercise Price of Derivative Security</p> | <p>5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)</p> | <p>6. Nature of Indirect Beneficial Ownership (Instr. 5)</p> |
|---|--|---|---|---|--|

Edgar Filing: eXegenics Inc - Form 3

(Instr. 5)

| | | | | | | | |
|-----------------------------------|--------------|--------------|--------------|------------|-----------|---|---|
| Series C Preferred Stock | 03/27/2007 | Â <u>(2)</u> | Common Stock | 12,973,600 | \$ 0 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Warrants to Purchase Common Stock | 03/27/2007 | 09/24/2014 | Common Stock | 810,849 | \$ 0.0193 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Warrants to Purchase Common Stock | 03/27/2007 | 07/01/2015 | Common Stock | 810,848 | \$ 0.0193 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Warrants to Purchase Common Stock | 03/27/2007 | 03/27/2017 | Common Stock | 265,489 | \$ 0.6728 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Warrants to Purchase Common Stock | 03/27/2007 | 03/27/2017 | Common Stock | 265,489 | \$ 0.8473 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Warrants to Purchase Common Stock | 03/27/2007 | 03/27/2017 | Common Stock | 265,489 | \$ 1.0466 | I | By Johnson & Johnson Development Corporation <u>(1)</u> |
| Stock Options (Right to Buy) | 03/27/2007 | 09/27/2007 | Common Stock | 5,189 | \$ 0.04 | I | by Johnson & Johnson Development Corporation <u>(1)</u> |
| Stock Options (Right to Buy) | 03/27/2007 | 09/27/2007 | Common Stock | 25,947 | \$ 0.04 | I | by Johnson & Johnson Development Corporation <u>(1)</u> |
| Stock Options (Right to Buy) | 03/27/2007 | 09/27/2007 | Common Stock | 103,788 | \$ 0.04 | I | by Johnson & Johnson Development Corporation <u>(1)</u> |
| Stock Options (Right to Buy) | Â <u>(3)</u> | 09/27/2007 | Common Stock | 5,189 | \$ 0.04 | I | by Johnson & Johnson Development Corporation <u>(1)</u> |
| Stock Options (Right to Buy) | Â <u>(4)</u> | 09/27/2007 | Common Stock | 155,682 | \$ 0.04 | I | by Johnson & Johnson Development Corporation <u>(1)</u> |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933 | ^ | ^ X | ^ | ^ |

Signatures

Douglas Chia, Assistant Secretary
04/06/2007

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
- (2) There is no expiration date applicable to the Series C Preferred Stock.
- (3) As of 3/27/07 vested as to 2,810 shares.
- (4) As of 3/27/07 vested as to 56,218 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.